• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺免疫预后指数在接受新辅助放化疗的局部晚期直肠癌患者中的预测和预后重要性评估

Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.

作者信息

Arıkan Rukiye, Alkış Hilal, Işık Selver, Yaşar Alper, Çelebi Abdussamet, Majidova Nargiz, Sever Nadiye, Adlı Mustafa, Demircan Nazım C

机构信息

Department of Medical Oncology, Marmara University School of Medicine, Istanbul, TUR.

Department of Radiation Oncology, Marmara University School of Medicine, Istanbul, TUR.

出版信息

Cureus. 2023 Jun 17;15(6):e40548. doi: 10.7759/cureus.40548. eCollection 2023 Jun.

DOI:10.7759/cureus.40548
PMID:37465788
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10350655/
Abstract

OBJECTIVE

The systemic inflammatory response (SIR) is known as an important factor associated with tumorigenesis and tumor progression, and can be reflected by inflammatory markers. One of the markers that reflect this is the lung immune prognostic index (LIPI). It is based on a derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) level. We aimed to investigate the significance of LIPI in locally advanced rectal cancer (LARC) patients treated with neoadjuvant chemoradiotherapy (NACRT).

METHODS

In this retrospective study, we stratified the patients according to LIPI score as good LIPI and intermediate (int)/poor LIPI. According to pathological response to NACRT, we divided the patients into two groups as those with complete response (CR) or near-CR, and those with partial response (PR) or poor/no response. We classified CR and near-CR as good response. We evaluated the predictive and prognostic significance of LIPI for NACRT response, disease-free survival (DFS), and overall survival (OS) by univariate and multivariate analyses.

RESULTS

We included 137 patients in the results, with 72 (52.6%) having good LIPI and 65 (47.4%) having int/poor LIPI. The median follow-up period was 44.7 months (range: 10-105 months). Thirteen patients (18.0%) in the good LIPI group and 22 patients (34.0%) in the int/poor LIPI group achieved good response. In multivariate analysis, we found only the LIPI score as an independent risk factor (hazard ratio (HR): 2.4, p = 0.04) for NACRT response. Median DFS was 89.2 months (95% CI: 11.4-167.0) in the int/poor LIPI group; however, the DFS of all study populations and patients in the good LIPI group did not reach the median value. In multivariate analysis for DFS, we identified abdominoperineal resection (APR) (HR: 2.21, p = 0.02), presence of tumor deposit (HR: 2.96, p = 0.003), and int/poor LIPI score (HR: 2.07, p = 0.02) as separate risk variables. OS of all study populations and the patients in the LIPI groups did not reach the median value. In multivariate analysis for OS, we identified APR (HR: 2.74, p = 0.02), surgical margin positivity (HR: 12.94, p < 0.001), and adjuvant CT (HR: 0.20, p = 0.002) as separate risk variables for OS.

CONCLUSION

This is the first study investigating the predictive and prognostic significance of LIPI in LARC patients treated with NACRT. The results revealed that int/poor LIPI was associated with a higher rate of good response but shorter DFS compared to good LIPI. The baseline LIPI score serves as an easily accessible and useful prognostic index, and it has significant potential for making appropriate treatment decisions in LARC.

摘要

目的

全身炎症反应(SIR)是与肿瘤发生和肿瘤进展相关的重要因素,可通过炎症标志物反映。反映这一情况的标志物之一是肺免疫预后指数(LIPI)。它基于推导的中性粒细胞与淋巴细胞比值(dNLR)和乳酸脱氢酶(LDH)水平。我们旨在研究LIPI在接受新辅助放化疗(NACRT)的局部晚期直肠癌(LARC)患者中的意义。

方法

在这项回顾性研究中,我们根据LIPI评分将患者分为LIPI良好组和中度/不良LIPI组。根据对NACRT的病理反应,我们将患者分为两组,即完全缓解(CR)或接近CR组,以及部分缓解(PR)或缓解不佳/无缓解组。我们将CR和接近CR归类为良好反应。我们通过单因素和多因素分析评估LIPI对NACRT反应、无病生存期(DFS)和总生存期(OS)的预测和预后意义。

结果

我们的结果纳入了137例患者,其中72例(52.6%)LIPI良好,65例(47.4%)中度/不良LIPI。中位随访期为44.7个月(范围:10 - 105个月)。LIPI良好组中有13例患者(18.0%)达到良好反应,中度/不良LIPI组中有22例患者(34.0%)达到良好反应。在多因素分析中,我们发现只有LIPI评分是NACRT反应的独立危险因素(风险比(HR):2.4,p = 0.04)。中度/不良LIPI组的中位DFS为89.2个月(95%置信区间:11.4 - 167.0);然而,所有研究人群和LIPI良好组患者的DFS未达到中位数。在DFS的多因素分析中,我们确定腹会阴联合切除术(APR)(HR:2.21,p = 0.02)、肿瘤结节的存在(HR:2.96,p = 0.003)和中度/不良LIPI评分(HR:2.07,p = 0.02)为独立的风险变量。所有研究人群和LIPI组患者的OS未达到中位数。在OS的多因素分析中,我们确定APR(HR:2.74,p = 0.02)、手术切缘阳性(HR:12.94,p < 0.001)和辅助化疗(HR:0.20,p = 0.002)为OS的独立风险变量。

结论

这是第一项研究LIPI在接受NACRT的LARC患者中的预测和预后意义的研究。结果显示,与LIPI良好组相比,中度/不良LIPI与更高的良好反应率相关,但DFS更短。基线LIPI评分是一个易于获取且有用的预后指标,在LARC中做出适当治疗决策方面具有重要潜力。

相似文献

1
Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.肺免疫预后指数在接受新辅助放化疗的局部晚期直肠癌患者中的预测和预后重要性评估
Cureus. 2023 Jun 17;15(6):e40548. doi: 10.7759/cureus.40548. eCollection 2023 Jun.
2
Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score.抗PD-1疗法治疗晚期胆管癌中一种全身炎症生物标志物的分析:肺免疫预后指数评分的预后和预测意义
J Oncol. 2022 Mar 17;2022:1427779. doi: 10.1155/2022/1427779. eCollection 2022.
3
Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.一线PD-1/PD-L1抑制剂联合化疗治疗的晚期小细胞肺癌患者治疗前肺免疫预后指数的预后价值
Front Oncol. 2021 Oct 8;11:697865. doi: 10.3389/fonc.2021.697865. eCollection 2021.
4
Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.治疗前肺免疫预后指数是化疗和表皮生长因子受体酪氨酸激酶抑制剂的预后标志物。
World J Oncol. 2019 Feb;10(1):35-45. doi: 10.14740/wjon1179. Epub 2019 Feb 26.
5
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.局部晚期非小细胞肺癌患者肺免疫预后指数与度伐利尤单抗巩固治疗结局的相关性。
Clin Lung Cancer. 2024 May;25(3):233-243.e8. doi: 10.1016/j.cllc.2023.11.007. Epub 2023 Nov 22.
6
Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy.肺免疫预后指数(LIPI)作为广泛期小细胞肺癌患者一线化疗免疫治疗的预后因素。
Clin Transl Oncol. 2025 Apr;27(4):1484-1492. doi: 10.1007/s12094-024-03690-3. Epub 2024 Sep 6.
7
Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection.术前肺免疫预后指数可预测接受根治性切除的胰腺癌患者的生存情况。
Front Surg. 2023 Jan 6;9:1002075. doi: 10.3389/fsurg.2022.1002075. eCollection 2022.
8
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.使用LIPI评分预测老年实体瘤患者的免疫治疗结果。
Cancers (Basel). 2022 Oct 17;14(20):5078. doi: 10.3390/cancers14205078.
9
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.验证肺免疫预后指数(LIPI)作为转移性肾细胞癌的预后生物标志物。
Eur J Cancer. 2024 Jun;204:114048. doi: 10.1016/j.ejca.2024.114048. Epub 2024 Apr 8.
10
A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer.肺免疫预后指数在局部晚期非小细胞肺癌患者预后评估中的验证研究。
Radiother Oncol. 2021 Mar;156:244-250. doi: 10.1016/j.radonc.2020.12.039. Epub 2021 Jan 5.

引用本文的文献

1
Development of a lung immune prognostic index-based nomogram model for predicting overall survival and immune-related adverse events in non-small cell lung cancer patients treated with sintilimab.基于肺免疫预后指数的列线图模型的开发,用于预测接受信迪利单抗治疗的非小细胞肺癌患者的总生存期和免疫相关不良事件。
Front Immunol. 2025 May 8;16:1569689. doi: 10.3389/fimmu.2025.1569689. eCollection 2025.

本文引用的文献

1
Analysis of Survival in Complete Pathological Response after Long-Course Chemoradiotherapy in Patients with Advanced Rectal Cancer.长程放化疗后完全病理缓解患者的生存分析:晚期直肠癌。
Curr Oncol. 2023 Jan 12;30(1):1054-1064. doi: 10.3390/curroncol30010081.
2
High Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Low Lymphocyte Levels Are Correlated With Worse Pathological Complete Response Rates.高中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及低淋巴细胞水平与较差的病理完全缓解率相关。
Cureus. 2022 Mar 8;14(3):e22972. doi: 10.7759/cureus.22972. eCollection 2022 Mar.
3
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification.
结直肠癌肿瘤沉积的全面概述:迈向新的 TNM 分类。
Cancer Treat Rev. 2022 Feb;103:102325. doi: 10.1016/j.ctrv.2021.102325. Epub 2021 Dec 21.
4
Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.肺免疫预后指数在接受一线阿替唑单抗联合治疗的非小细胞肺癌患者中的价值:IMPOWER150试验的亚组分析
Cancers (Basel). 2021 Mar 9;13(5):1176. doi: 10.3390/cancers13051176.
5
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.预处理肺免疫预后指数与接受PD-1抑制剂治疗的晚期肝细胞癌患者生存结局的关联
J Hepatocell Carcinoma. 2020 Nov 2;7:289-299. doi: 10.2147/JHC.S277453. eCollection 2020.
6
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.肺免疫预后指数可区分接受免疫检查点抑制剂治疗的实体瘤患者的生存结局。
Cancers (Basel). 2019 Nov 2;11(11):1713. doi: 10.3390/cancers11111713.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.肺免疫预后指数与晚期非小细胞肺癌患者免疫检查点抑制剂疗效的相关性。
JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.
9
Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.系统免疫炎症指数预测 III 期非小细胞肺癌患者的放化疗耐药和不良预后。
J Transl Med. 2017 Oct 31;15(1):221. doi: 10.1186/s12967-017-1326-1.
10
Prognostic role of the lymphocyte-to-monocyte ratio in colorectal cancer: An up-to-date meta-analysis.淋巴细胞与单核细胞比值在结直肠癌中的预后作用:一项最新的荟萃分析。
Medicine (Baltimore). 2017 Jun;96(22):e7051. doi: 10.1097/MD.0000000000007051.